Founding Sponsors

EDUCATION

Dashboard

Video Courses

State of the Art

Limited Series

Podcasts

Case Studies

Quiz Archive

Knowledge Assessments

Featured Highlights

RESOURCES

Late Breakers

Drug & Product Resources

Ask the Expert

Faculty

Founding Sponsors

Late Breakers

Top 5 Industry Updates

Lipid Peroxidation: A Double-Edged Sword in Skin Disease Pathogenesis

Lipid peroxidation is a key player in both inflammatory and neoplastic skin diseases, with emerging potential for therapeutic targeting and AI-driven insights.

Nemolizumab Shows “Sustained and Increased” Improvements in Itch and Skin Lesions in AD Patients for Up to Two Years

The IL-31 blocker was well tolerated in the long-term treatment of atopic dermatitis, and no new safety signals were identified.

Industry Information

New Data Show 40-Gene Expression Profile (DecisionDx®-SCC) Identifies Cutaneous Squamous Cell Carcinoma Patients Most Likely to Benefit from Adjuvant Radiation Therapy

Study results demonstrate that DecisionDx-SCC can identify high-risk cutaneous squamous cell carcinoma patients who are most likely to benefit from adjuvant radiation therapy.

Cemiplimab Performs Well in High-risk cSCC in the Adjuvant Setting

Cemiplimab produced a statistically significant and clinically meaningful benefit in high-risk cutaneous squamous cell carcinoma (CSCC) after surgery, according to the Phase 3 C-POST tria

Industry Information

Biofrontera Announces the Launch of a New, FDA-Approved Red Light Source, the RhodoLED® XL Lamp

The RhodoLED® XL is approved by the FDA in combination with AMELUZ® (aminolevulinic acid hydrochloride) topical gel, 10% for photodynamic therapy (PDT) of actinic keratoses of mild-to-moderate severity on the face and scalp and is now commercially available.

Seeing Smarter: How Explainable AI Boosts Melanoma Detection

Eye-tracking study shows that explainable AI boosts melanoma diagnostic accuracy and changes how dermatologists visually engage with diagnostic tools.

Central Adiposity Linked to PsO Risk

Study findings highlight potential role of glucagon-like peptide-1 receptor agonists for reducing psoriasis morbidity.

Long-Term Skin Clearance with Tapinarof in Atopic Dermatitis: 48-Week Extension Data

Phase 3 results show long-term potential of Tapinarof as a nonsteroidal, once-daily topical option for AD across a broad age range.

Etanercept Meaningfully Improves Patient Quality of Life in Psoriasis

A multinational phase III trial found that etanercept significantly improved both clinical symptoms and patient-reported quality of life in individuals with moderate-to-severe psoriasis.

Targeting Th2 Pathways in Netherton Syndrome: Insights from Dupilumab Intervention

A recent exploratory study evaluates the therapeutic potential of IL-4/IL-13 inhibition via dupilumab for NS and reinforces the central role of Th2-driven mechanisms in NS .

Scissor Excision Outperforms 532 nm LBO Laser for Skin Tag Removal: A Randomized Split-Site Study

A comparative study evaluates the effectiveness, cosmetic outcomes, and patient satisfaction between traditional scissor snip excision and the non-ablative 532 nm long-pulsed LBO laser.

Stem Cell Therapy Shows Wound Healing Boost, Raises Long-Term Questions

A new preclinical study investigates whether combining collagen III with adipose-derived stem cells enhances vascular regeneration and wound repair.

Targeting Acne from Within: Nutraceutical Shows Results in 12-Week Study

A recent study shows nutraceutical significantly improves mild to moderate acne as well as other parameters of skin appearance

U.S. FDA Approves Roflumilast Foam 0.3% (Zoryve, Arcutis) for Plaque Psoriasis of the Scalp and Body

Roflumilast topical foam 0.3% is uniquely formulated for use anywhere on the body, including hair-bearing areas, and is now indicated for treatment of plaque psoriasis of the scalp and body in patients 12 years of age and up.

Single-Cell RNA Sequencing Distinguishes Allergic from Irritant Contact Dermatitis

A recently published study demonstrated that protein and transcriptomic markers could distinguish ACD from ICD with high sensitivity and specificity, laying the groundwork for future diagnostic tools that could augment or replace current patch testing approaches.

U.S. FDA Approves Sun Pharma’s Next Generation BLU-U Blue Light PDT Illuminator for AK

LED BLU-U, in combination with LEVULAN KERASTICK (aminolevulinic acid HCl) Topical Solution, 20%, is indicated for the treatment of minimally to moderately thick AK of the face, scalp, or upper extremities as is the previous model.

Temtokibart Hits Key Endpoints in Phase 2b Trial for Atopic Dermatitis

In a dose-ranging study, the three highest dosing arms of temtokibart met the primary endpoint of percent change from baseline in EASI score at week 16 versus placebo.

New Oral JAK Inhibitor Shows Promise in Atopic Dermatitis

A recent phase 3 clinical trial highlights the potential of ivarmacitinib, an investigational oral JAK1-selective inhibitor, as a treatment for moderate to severe atopic dermatitis (AD).

Precision Medicine in Psoriasis: Mindera Health’s Mind.Px Test Changes Physician Behavior, Improves Outcomes

An analysis of patients whose physicians followed Mind.Px results showed that more patients reached the clinical endpoint (PASI75) at 12 weeks and improved faster, with patients reaching this endpoint by Week 4.

Oral IL-23 Blocker Icotrokinra Produces Significant Skin Clearance in Patients with Scalp and Genital PsO

Fully 57% of patients treated with once daily icotrokinra achieved the study's primary endpoint with an IGA score of 0/1 and a ≥2-grade improvement from baseline at Week 16 compared to 6% of patients receiving placebo.

New Data Show Roflumilast Foam 0.3% (Zoryve, Arcutis) Improves Scalp and Body Pso Symptoms, Including Itch

Roflumilast foam is under review for the treatment of scalp and body psoriasis by the FDA with a PDUFA target action date of May 22, 2025.

Delgocitinib Cream Shows Superior Efficacy and Safety in Treating Severe Chronic Hand Eczema

Phase 3 trials reveal delgocitinib cream significantly outperforms oral alitretinoin for chronic hand eczema.

U.S. FDA Approves Zevaskyn, the First and Only FDA-approved Product for Recessive Dystrophic Epidermolysis Bullosa

There is no cure for RDEB, and Zevaskyn is the only FDA-approved product to treat RDEB wounds with a single application.

Chronic Hand Eczema Affects Patients’ Emotional, Social, and Occupational Well-Being

Ninety-five percent of U.S. dermatology providers agree that moderate-to-severe chronic hand eczema (CHE) has a strong impact on patients’ work and home life, a new survey shows.

U.S. FDA Approves Dupilumab (Dupixent, Sanofi & Regeneron) for CSU, Marking the Seventh Disease State Approval for the IL-4 and IL-13 Blocker

Dupilumab is first targeted therapy to be approved for CSU in a decade.

Deuruxolitinib (Leqselvi, Sun Pharma) Update: Injunction Lifted, Clearing the Way for a Potential Launch

The preliminary injunction is no longer in effect, but the litigation between Incyte and Sun Pharma is ongoing

Once-daily Oral Icotrokinra Shows Efficacy in Adolescents With Moderate to Severe PsO

Three-quarters of adolescents with PsO treated with investigational icotrokinra (JNJ-2113) achieved completely clear skin with no new safety signals identified, according to data from a subgroup analysis of ICONIC-LEAD.

Confirmed: Castle Biosciences’ DecisionDx-Melanoma Test’s Ability to ID Patients Who Can Safely Forgo SLNB

Two new studies confirm that Castle’s DecisionDx-Melanoma test can accurately identify patients with less than 5% risk of SLN positivity who can safely consider forgoing the SLNB and who are also unlikely to experience disease progression.

Unraveling the Role of Type 2 Inflammation in AD, PN, and CSU

AD, PN, and CSU are unified by a dysregulated type 2 immune response that involves type 2 cytokines such as IL–4, IL–3, and IL–31 interacting with immune cells, sensory nerves, keratinocytes, fibroblasts, and other cells of the skin.

Bimekizumab-bkzx (Bimzelx, UCB) Demonstrates Sustained Skin Clearance in Moderate-to-severe Plaque PsO

Fully 67.7% of patients with moderate-to-severe plaque psoriasis on bimekizumab achieved PASI 100+ at five years

Inside the HS Pipeline: Incyte’s Povorcitinib Hits Primary Endpoints in Phase 3 Studies

A significantly higher proportion of patients treated with povorcitinib once daily (QD) vs. placebo achieved HiSCR, a ≥50% reduction from baseline in the total AN count, with no increase from baseline in abscess or draining tunnel count.

Please Provide Feedback

Late Breakers

Top 5 Industry Updates

Lipid Peroxidation: A Double-Edged Sword in Skin Disease Pathogenesis

Nemolizumab Shows “Sustained and Increased” Improvements in Itch and Skin Lesions in AD Patients for Up to Two Years

Industry Information

New Data Show 40-Gene Expression Profile (DecisionDx®-SCC) Identifies Cutaneous Squamous Cell Carcinoma Patients Most Likely to Benefit from Adjuvant Radiation Therapy

Cemiplimab Performs Well in High-risk cSCC in the Adjuvant Setting

Industry Information

Biofrontera Announces the Launch of a New, FDA-Approved Red Light Source, the RhodoLED® XL Lamp

Seeing Smarter: How Explainable AI Boosts Melanoma Detection

Read More

Central Adiposity Linked to PsO Risk

Long-Term Skin Clearance with Tapinarof in Atopic Dermatitis: 48-Week Extension Data

Etanercept Meaningfully Improves Patient Quality of Life in Psoriasis

Targeting Th2 Pathways in Netherton Syndrome: Insights from Dupilumab Intervention

Scissor Excision Outperforms 532 nm LBO Laser for Skin Tag Removal: A Randomized Split-Site Study

Stem Cell Therapy Shows Wound Healing Boost, Raises Long-Term Questions

Targeting Acne from Within: Nutraceutical Shows Results in 12-Week Study

U.S. FDA Approves Roflumilast Foam 0.3% (Zoryve, Arcutis) for Plaque Psoriasis of the Scalp and Body

Single-Cell RNA Sequencing Distinguishes Allergic from Irritant Contact Dermatitis

U.S. FDA Approves Sun Pharma’s Next Generation BLU-U Blue Light PDT Illuminator for AK

Temtokibart Hits Key Endpoints in Phase 2b Trial for Atopic Dermatitis

New Oral JAK Inhibitor Shows Promise in Atopic Dermatitis

Precision Medicine in Psoriasis: Mindera Health’s Mind.Px Test Changes Physician Behavior, Improves Outcomes

Oral IL-23 Blocker Icotrokinra Produces Significant Skin Clearance in Patients with Scalp and Genital PsO

New Data Show Roflumilast Foam 0.3% (Zoryve, Arcutis) Improves Scalp and Body Pso Symptoms, Including Itch

Delgocitinib Cream Shows Superior Efficacy and Safety in Treating Severe Chronic Hand Eczema

U.S. FDA Approves Zevaskyn, the First and Only FDA-approved Product for Recessive Dystrophic Epidermolysis Bullosa

Chronic Hand Eczema Affects Patients’ Emotional, Social, and Occupational Well-Being

U.S. FDA Approves Dupilumab (Dupixent, Sanofi & Regeneron) for CSU, Marking the Seventh Disease State Approval for the IL-4 and IL-13 Blocker

Deuruxolitinib (Leqselvi, Sun Pharma) Update: Injunction Lifted, Clearing the Way for a Potential Launch

Once-daily Oral Icotrokinra Shows Efficacy in Adolescents With Moderate to Severe PsO

Confirmed: Castle Biosciences’ DecisionDx-Melanoma Test’s Ability to ID Patients Who Can Safely Forgo SLNB

Unraveling the Role of Type 2 Inflammation in AD, PN, and CSU

Bimekizumab-bkzx (Bimzelx, UCB) Demonstrates Sustained Skin Clearance in Moderate-to-severe Plaque PsO

Inside the HS Pipeline: Incyte’s Povorcitinib Hits Primary Endpoints in Phase 3 Studies